首页> 外文期刊>Acta Neurochirurgica >Pre-operative neutrophil count and neutrophil-lymphocyte count ratio (NLCR) in predicting the histological grade of paediatric brain tumours: a preliminary study
【24h】

Pre-operative neutrophil count and neutrophil-lymphocyte count ratio (NLCR) in predicting the histological grade of paediatric brain tumours: a preliminary study

机译:预测性中性粒细胞计数和中性粒细胞淋巴细胞计数比(NLCR)预测小儿脑肿瘤的组织学等级:初步研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Introduction The neutrophil-lymphocyte count ratio (NLCR) is an established prognostic marker for renal, lung and colorectal carcinomas and has been suggested to be predictive of histological grade and outcome in adult intracranial tumours. The purpose of this study was to determine whether a correlation of the pre-operative neutrophil count (NC) and NLCR with the final histological grade exists in paediatric intracranial tumours. Methods A retrospective analysis was undertaken at a single centre. Patients less than 18?years old at the time of surgery who underwent tumour-related procedures from 2006 to 2015 were included. Patients with recurrent tumours, previous bone marrow transplant and metastases were excluded. Pre-operative full blood counts (FBC), collected before the diagnosis of intracranial pathology and before administration of steroids, were matched with histological diagnosis for each patient. Post-operative FBC was also recorded, together with survival data where applicable. Results A total of 116 patients (74 male, 42 female; mean age, 8?±?0.9?years) with a diagnosis of primary intracranial tumours had pre-operative FBC that could be matched to final histological grade. Pre-operative NC and NLCR were higher with increasing grade of tumour: grade 1 (NC 4.29 10_(9)/l, NLCR 2.26), grade 2 (NC 4.59 10_(9)/l, NLCR 2.38), grade 3 (NC 5.67 10_(9)/l, NLCR 2.72) and grade 4 (NC 6.59 10_(9)/l, NLCR 3.31). Patients with WHO grade 1 and 2 tumours pooled together had a lower NC (4.37 95% CI?±?0.67 10_(9)/l) compared to WHO grade 3 and 4 patients (6.41 95% CI?±?0.99 10_(9)/l, p ?=?0.0013). The NLCR was lower in grade 1 and 2 tumours (2.29?±?0.59) (compared to grade 3 and 4 tumours; 3.20?±?0.76) but this did not reach significance ( p ?=?0.069). The subgroup of patients with pilocytic astrocytoma had a significantly lower NC when compared to patients with high-grade tumours ( p ?=?0.005). Medulloblastoma and supratentorial PNET subgroups had significantly higher NC compared to the low-grade group ( p ?=?0.033, p ?=?0.002). Post-operative NC was significantly higher in the high-grade tumours ( p ?=?0.034), but no difference was observed for NLCR ( p ?=?0.28). Conclusions No evidence exists to support the correlation of pre-operative NC or NLCR to histological diagnosis in paediatric intracranial tumours. Our results indicate that a higher pre-operative NC/NLCR correlates with a higher histological grade of tumour. This suggests that immunological mechanisms may be involved in the pathogenesis of paediatric brain tumours, and a further prospective study is required to substantiate and expand these findings.
机译:摘要引言中性粒细胞淋巴细胞计数比(NLCR)是肾,肺和结肠直肠癌癌的建立的预后标志物,并已建议预测成人颅内肿瘤的组织学等分和结果。本研究的目的是确定具有最终组织学等级的术前中性粒细胞计数(NC)和NLCR的相关性是否存在于儿科颅内肿瘤中。方法在单一中心进行回顾性分析。患者少于18岁?在手术时历史,他们在2006年到2015年接受了相关的肿瘤相关程序。患有复发性肿瘤的患者,以前的骨髓移植和转移被排除在外。在颅内病理学诊断之前收集的术前全血计(FBC)和施用类固醇,与每位患者的组织学诊断相匹配。操作后的FBC也被记录,加上适用的生存数据。结果总共116名患者(74名男性,42例女性;平均年龄,8?±0.9岁,8〜±0.9岁)具有初发性颅内肿瘤的诊断性FBC可与最终组织学等级匹配。术前Nc和Nlcr随着肿瘤等级的增加:1级(NC 4.29 10_(9)/ L,NLCR 2.26),2级(NC 4.59 10_(9)/ L,NLCR 2.38),3年级(NC 5.67 10_(9)/ L,NLCR 2.72)和4级(NC 6.59 10_(9)/ L,NLCR 3.31)。与世卫组织3和4名患者相比,合并的1级和2级肿瘤的患者汇总在一起的NC(4.37 95%CI?±0.6710_(9)/ L)(6.41 95%CI?±0.99 10_(9 )/ l,p?= 0.0013)。 NLCR在1级和2级肿瘤(2.29?±0.59)(与4级和4级肿瘤相比; 3.20?±0.76),但这没有达到意义(P?= 0.069)。与高级肿瘤患者相比,含蝇星形细胞瘤患者的患者的亚组具有显着降低的NC(P?= 0.005)。与低级组相比,Medulloblastoma和SuprateLential PNET亚组的NC显着更高(p?= 0.033,p?= 0.002)。在高级肿瘤中术后NC显着较高(P?= 0.034),但NLCR没有观察到差异(p?= 0.28)。结论不存在证据支持术前NC或NLCR与儿科颅内肿瘤组织学诊断的相关性。我们的结果表明,更高的术前NC / NLCR与更高的组织学等级相关的肿瘤。这表明免疫机制可能参与小儿脑肿瘤的发病机制,并且需要进一步的前瞻性研究来证实和扩大这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号